Title: ADAPT Act of 2018
Policy area: Crime and Law Enforcement

Summary:
Abuse Deterrent and Prescriber Training Act of 2018 or the ADAPT Act of 2018
This bill amends the Controlled Substances Act to prohibit the Drug Enforcement Administration from registering, or renewing the registration of, a practitioner who is licensed to prescribe opioids in schedule II, III, IV, or V unless the practitioner completes a training program that includes information on opioids.
The Government Accountability Office must report to Congress on the effects of the amendments made by this bill, including whether there has been a reduction in opioids prescribed and in opioid-related overdoses and death.

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5581 Introduced in House (IH)]

<DOC>






115th CONGRESS
  2d Session
                                H. R. 5581

 To require training for prescribers of controlled substances, and for 
                            other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 23, 2018

 Mrs. Brooks of Indiana (for herself and Mr. Schneider) introduced the 
   following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on the Judiciary, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL


 
 To require training for prescribers of controlled substances, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Abuse Deterrent and Prescriber 
Training Act of 2018'' or the ``ADAPT Act of 2018''.

SEC. 2. PRACTITIONER EDUCATION.

    (a) In General.--Part C of the Controlled Substances Act (21 U.S.C. 
821 et seq.) is amended--
            (1) in section 303 (21 U.S.C. 823), by adding at the end 
        the following:
    ``(k)(1) The Attorney General shall not register, or renew the 
registration of, a practitioner under subsection (f) who is licensed 
under State law to prescribe controlled substances in schedule II, III, 
IV, or V, unless the practitioner submits to the Attorney General, for 
each such registration or renewal request, a written certification that 
the practitioner has completed 3 hours of training under a training 
program meeting the criteria in paragraph (2) during the period 
applicable under paragraph (5).
    ``(2) A training program meets the criteria in this paragraph if 
the program--
            ``(A) includes information on--
                    ``(i) safe opioid prescribing guidelines, including 
                the Guideline for Prescribing Opioids for Chronic Pain 
                issued by the Centers for Disease Control and 
                Prevention;
                    ``(ii) the risks of opioid medications and other 
                prescription drugs that are controlled substances;
                    ``(iii) pain management, including the need to 
                provide individualized care particularly for active 
                cancer treatment, palliative care, and end-of-life 
                care;
                    ``(iv) early detection of opioid and other 
                substance use disorders;
                    ``(v) the risks of prescribing opioids to any 
                individual in recovery from a substance use disorder;
                    ``(vi) a basic understanding of addiction;
                    ``(vii) the treatment of opioid-dependent patients 
                and their treatment options;
                    ``(viii) the risks of misuse of all prescription 
                drugs that are controlled substances; and
                    ``(ix) alternative non-opioid pain management 
                medications and other effective treatments; and
            ``(B) is--
                    ``(i) approved by the State agency with primary 
                responsibility for licensing the practitioner to 
                prescribe controlled substances; or
                    ``(ii) if such State agency does not have in effect 
                an approval of any training program for purposes of 
                this subsection, conforms to the model training program 
                in effect under paragraph (4).
    ``(3) Notwithstanding paragraph (2), a training program on 
prescribing opioids used by a State for purposes of licensing health 
care practitioners is deemed to meet the criteria in paragraph (2) if 
the program has been in effect since before the date of enactment of 
the Abuse Deterrent and Prescriber Training Act of 2018.
    ``(4) The Secretary of Health and Human Services shall--
            ``(A) by not later than 60 days after the date of enactment 
        of the Abuse Deterrent and Prescriber Training Act of 2018, 
        develop a model training program on prescribing opioids to be 
        used for purposes of paragraph (2)(B)(ii); and
            ``(B) by not later than 90 days after such date of 
        enactment, provide information about such model training 
        program to the Attorney General, prescribers, State licensing 
        boards, and continuing medical education providers.
    ``(5)(A) In the case of a registration request, and in the case of 
the first renewal request of a practitioner after the date of enactment 
of the Abuse Deterrent and Prescriber Training Act of 2018, the 
training required by paragraph (1) shall occur during the 1-year period 
preceding the registration or first renewal request.
    ``(B) In the case of a renewal request that is not the first 
renewal request of a practitioner after such date of enactment, the 
training required by paragraph (1) shall occur during the 3-year period 
preceding the renewal request.
    ``(6) The Attorney General may--
            ``(A) take steps necessary to verify that a practitioner 
        has completed a training program as required under paragraph 
        (1), including requiring a practitioner to provide information 
        determined necessary by the Attorney General; and
            ``(B) investigate a practitioner described in paragraph (1) 
        if the Attorney General has reason to believe the practitioner 
        filed an inaccurate or fraudulent written certification under 
        paragraph (1).
    ``(7) Nothing in this subsection shall be construed to prevent a 
practitioner from using the same training both for purposes of 
satisfying the registration requirements of this subsection and for 
other purposes, such as satisfying State licensing requirements.''; and
            (2) in section 304(a) (21 U.S.C. 824(a)), by adding at the 
        end the following:
``A registration pursuant to section 303(f) issued to a practitioner 
who is required to comply with section 303(k) may be denied or revoked 
by the Attorney General upon a finding that the practitioner has failed 
to comply with section 303(k).''.
    (b) Effective Date.--The amendments made by subsection (a) shall 
take effect on the date that is 180 days after the date of enactment of 
this Act.
    (c) Sunset.--Effective on the date that is 5 years after the date 
of enactment of this Act, the following provisions are repealed:
            (1) Subsection (k) of section 303 of the Controlled 
        Substances Act (21 U.S.C. 823), as added by subsection (a)(1) 
        of this section.
            (2) The sentence added by subsection (a)(2) of this section 
        to the end of section 304(a) of such Act (21 U.S.C. 824(a)).

SEC. 3. REPORT TO CONGRESS.

    Not later than 2 years after the date of enactment of this Act, the 
Comptroller General of the United States shall submit a report to 
Congress on the effects of this Act and the amendments made by this 
Act, including an analysis of--
            (1) whether there has been a reduction in the volume of 
        opioids prescribed;
            (2) whether there has been an increase in the likelihood 
        that opioid-dependent patients receive substance use disorder 
        treatment;
            (3) whether there has been a reduction in opioid-related 
        overdoses and deaths;
            (4) whether training required by this Act and the 
        amendments made by this Act has changed prescribing practices 
        and increased patient referrals to treatment; and
            (5) the extent to which prescribers have conformed their 
        practices to those recommended in training pursuant to this Act 
        and the amendments made by this Act.
                                 <all>